Table 4.
Summary of maximum viral RNA load per location and COVID19 clinical severity
| Author | URT | LRT | Faeces | Blood |
|---|---|---|---|---|
| Maximum viral copies/mL [log 10] on Day after symptom onset | ||||
| Mild | ||||
| Woelfel et al. [7]a | ∼ 6•61 × 108 on Day 4 (6•66 × 108 in publ.) | ∼ 2•69 × 108 on Day 6 (7•11 × 108 copies/swab in publ.) | ∼ 3•55 × 107 on Day 9 | ND |
| Zou [13]# | ∼ 2•19 × 107 on Day 4 | ND | ND | ND |
| G. Lui et al. [20],* | 2•50 × 106 on Day 4 | ND | 7•94 × 103 on Day 7 | ND |
| Zheng et al.[12],a | ND | ∼ 2•00 × 107 on Day 11 | ND | ND |
| Moderate-Severe | ||||
| Woelfel et al [7]a | ND | ND | ND | ND |
| Zou [13]a | ∼ 1•32 × 108 on Day 5 | ND | ND | ND |
| G. Lui et al. [20],* | 4•60 × 109 on Day 8 | 3•45 × 108 on Day 11 | 2•76 × 106 on Day 18 | 1 × 104 on Day 3 |
| Zheng et al. [12]a | ND | ∼1•82 × 106 on Day 4 | ND | ND |
LRT: Lower respiratory tract, ND: Not determined, URT: Upper respiratory tract;
⁎
all subjects in this study received Lopinavir/Ritonavir; LRT: Lower respiratory tract, ND: Not determined, publ.: Publication; URT: Upper respiratory tract;
a
estimated data as digitalized from graph. Number in brackets refer to listing in reference list.